Al-Ola Abdallah, MD

Al-Ola Abdallah, MD, is an associate professor, Hematologic Malignancies and Cellular Therapeutics, and clinical director, Plasma Cell Disorder Program, at the University of Kansas Medical Center.

Articles by Al-Ola Abdallah, MD

Safety of IMiD-Based Holding Therapy Before CAR T-Cell Therapy in Multiple Myeloma

ByAl-Ola Abdallah, MD

October 13th 2026

Al-Ola Abdallah, MD, discusses IMiD-based holding therapy before leukapheresis and its safety in patients with myeloma receiving CAR T-cell therapy.

Al-Ola Abdallah, MD

Articles by Al-Ola Abdallah, MD

Safety of IMiD-Based Holding Therapy Before CAR T-Cell Therapy in Multiple Myeloma

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test

FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases

As New TGCT Therapies Advance, Route, Duration, and Coverage Shape CSF1R Inhibitor Choice

Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs

Dr Morgans on Cognitive Effects of Darolutamide vs Enzalutamide in Prostate Cancer